REG - Assura plc - Issue of Consideration Shares

AssuraAnnouncement

06/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220406:nRSF3927Ha&default-theme=true

RNS Number : 3927H  Assura PLC  06 April 2022

6 April 2022

Assura plc

Issue of Consideration Shares

Assura plc ("Assura" or "the Company"), the UK's leading primary care property
investor and developer, today announces that it has issued 3,331,539 ordinary
shares of 10 pence each (the "New Shares") as part consideration for the
acquisition of a medical centre via a corporate vehicle.

Application has therefore been made for the admission of the New Shares to the
Official List of the Financial Conduct Authority and to trading on the main
market for listed securities of the London Stock Exchange plc ("Admission").
The New Shares will rank pari passu with the Company's existing ordinary
shares and Admission is expected to occur at 8.00am on 7 April 2022.

Following the allotment of the New Shares, it is expected that the total
number of shares in issue will be 2,951,691,176 (none of which will be held in
treasury) and that, accordingly, the total number of voting rights of the
Company will be 2,951,691,176. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they will
determine whether they are required to notify their interests in, or a change
to their interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

- ENDS -

For more information, please contact:

 Assura plc                                  Tel: 01925 945354
 Orla Ball, Company Secretary                Email: Investor@assura.co.uk

David Purcell, Head of Investor Relations
 Finsbury Glover Hering                      Tel: 0207 251 3801

                                           Email: Assura@Finsbury.com
 Gordon Simpson

James Thompson

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT
and long-term investor in and developer of primary care property. The company,
headquartered in Warrington, works with GPs, health professionals and the NHS
to create innovative property solutions in order to facilitate delivery of
high quality patient care in the community. At 30 September 2021, Assura's
property portfolio was valued at £2,595 million.

 

 

 

Further information is available at www.assuraplc.com
(http://www.assuraplc.com)

*EPRA is a registered trademark of the European Public Real Estate
Association

Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXLSESLAEFA